拓扑异构酶与肿瘤多药耐药及耐药逆转

被引:5
作者
胡静
钱晓萍
刘宝瑞
臧秦川
机构
[1] 南京中医药大学附属鼓楼医院肿瘤中心
关键词
DNA拓扑异构酶类; 药物耐受性; 抗肿瘤药;
D O I
暂无
中图分类号
R730.53 [化学(药物)疗法];
学科分类号
100214 ;
摘要
多药耐药(MDR)的产生是肿瘤化疗失败的主要原因。拓扑异构酶Ⅱ(topoⅡ)介导的 MDR为MDR的重要途径。耐药逆转剂的应用是克服肿瘤临床耐药,提高化疗效果的一种潜在的重 要手段。现综述topoⅡ与肿瘤MDR及耐药逆转研究进展。
引用
收藏
页码:110 / 113
页数:4
相关论文
共 16 条
[1]  
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Van Hattum AH,Pinedo HM,Schluper HM,et al. International Journal of Cancer . 2000
[2]  
In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase Ⅰ and Ⅱ. Mistry P,Stewart AJ,Dangerfield W,et al. Anti Cancer Drugs . 2002
[3]  
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Hoki Y,Fujimori A,Pommier Y. Cancer Chemother . 1997
[4]  
Markers of drug resistance in relapsing colon cancer. Lazaris AC,Kavantzas NG,Zorzos HS,et al. Journal of Cancer Research and Clinical Oncology . 2002
[5]  
Incidence of muta-tion and deletionin topoisomeraseⅡalpha mRNA of etoposide and mAMSA-resistant cell lines. Matsumoto Y,Takano H,Kunishio K,et al. Japanese Journal of Cancer Research . 2001
[6]  
Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine. Kang MR,Chung IK. Molecular Pharmacology . 2002
[7]  
Transcription factor c-Jun activation repres- ses mdr-1 gene expression. MIAO ZH,DING J. Cancer Research . 2003
[8]  
Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells. Matsurmoto Y,Takano H,Kunishio K,et al. Japanese Journal of Cancer Research . 2001
[9]  
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase Ⅱ-directed drugs. Ogiso Y,Tomida A,Tsuruo T. Cancer Research . 2002
[10]  
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. Liu B,Staren ED,Iwamura T,et al. Journal of Surgical Research . 2001